MA46750A - Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents - Google Patents

Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents

Info

Publication number
MA46750A
MA46750A MA046750A MA46750A MA46750A MA 46750 A MA46750 A MA 46750A MA 046750 A MA046750 A MA 046750A MA 46750 A MA46750 A MA 46750A MA 46750 A MA46750 A MA 46750A
Authority
MA
Morocco
Prior art keywords
ralinepag
agents
combinations
methods
treating pah
Prior art date
Application number
MA046750A
Other languages
English (en)
French (fr)
Inventor
John W Adams
Dominic P Behan
Lucie H Clapp
Original Assignee
Arena Pharm Inc
Lucie H Clapp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc, Lucie H Clapp filed Critical Arena Pharm Inc
Publication of MA46750A publication Critical patent/MA46750A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA046750A 2016-11-10 2017-11-10 Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents MA46750A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662420515P 2016-11-10 2016-11-10
US201762530533P 2017-07-10 2017-07-10

Publications (1)

Publication Number Publication Date
MA46750A true MA46750A (fr) 2019-09-18

Family

ID=60451197

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046750A MA46750A (fr) 2016-11-10 2017-11-10 Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents

Country Status (10)

Country Link
US (1) US12377067B2 (enExample)
EP (1) EP3538154B1 (enExample)
JP (3) JP2019533713A (enExample)
KR (3) KR20200015439A (enExample)
CN (2) CN119367341A (enExample)
AU (2) AU2017357759A1 (enExample)
CA (1) CA3043283A1 (enExample)
IL (2) IL266518A (enExample)
MA (1) MA46750A (enExample)
WO (1) WO2018089804A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017357759A1 (en) 2016-11-10 2019-06-06 Arena Pharmaceuticals, Inc. Methods of treating PAH with combinations of ralinepag and other agents
KR102432505B1 (ko) 2017-03-01 2022-08-12 아레나 파마슈티칼스, 인크. Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법
WO2019222764A1 (en) * 2018-05-16 2019-11-21 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
CN108721296B (zh) * 2018-07-03 2019-04-05 中国人民解放军总医院 一种化合物在治疗或预防高原病中的用途
CN112638865B (zh) * 2018-09-06 2022-07-26 广东东阳光药业有限公司 药物共晶体及其制备方法
MX2021007455A (es) 2018-12-21 2021-08-05 Actelion Pharmaceuticals Ltd Composicion farmaceutica para el tratamiento de hipertension arterial pulmonar.
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
US20250282716A1 (en) 2024-03-11 2025-09-11 United Therapeutics Corporation Methods of making ip-receptor agonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085844A1 (en) 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
WO2002055484A1 (en) 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Biaryl compound, process for producing the same, and agent
US20030144350A1 (en) 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
EP1431267A4 (en) 2001-08-09 2004-12-22 Ono Pharmaceutical Co COMPOUNDS DERIVED FROM CARBOXYLIC ACID AND MEDICAMENTS COMPRISING SUCH COMPOUNDS AS ACTIVE INGREDIENT
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TWI293715B (en) 2002-10-10 2008-02-21 Sipix Imaging Inc A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display
CN101723891A (zh) 2003-02-10 2010-06-09 沃泰克斯药物股份有限公司 通过使n-芳基氨基甲酸酯与卤代杂芳基反应制备n-杂芳基-n-芳基胺的方法和类似方法
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
JP2008510726A (ja) 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
WO2007051255A1 (en) 2005-11-04 2007-05-10 The University Of Sydney Process for the preparation of compounds containing an azacyclic ring system
US20080075692A1 (en) 2006-05-09 2008-03-27 Perrine Susan P Methods for treating blood disorders
KR20220031743A (ko) 2008-03-18 2022-03-11 아레나 파마슈티칼스, 인크. 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제
BRPI0921369B8 (pt) 2008-11-26 2021-05-25 Arena Pharm Inc composto modulador do receptor de prostaciclina (pgi2), sua composição, sua composição farmacêutica, seus usos, bem como processos para a preparação das referidas composições
ES2548882T3 (es) 2008-12-08 2015-10-21 Arena Pharmaceuticals, Inc. Moduladores del receptor de prostaciclina (PGl2) útiles para el tratamiento de trastornos relacionados con los mismos
EP2480526A1 (en) * 2009-09-23 2012-08-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
US9388154B2 (en) * 2011-09-12 2016-07-12 Lund Biotechnology PBC Process for preparing synthetic prostacyclins
JP6357481B2 (ja) * 2012-11-30 2018-07-11 インスメッド， インコーポレイテッド プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法
NZ731751A (en) 2014-10-23 2023-07-28 Arena Pharm Inc Method of treating conditions related to the pgi2 receptor
WO2016114993A1 (en) * 2015-01-13 2016-07-21 Selten Pharma, Inc. Combination therapy for pulmonary hypertension
AU2017357759A1 (en) 2016-11-10 2019-06-06 Arena Pharmaceuticals, Inc. Methods of treating PAH with combinations of ralinepag and other agents

Also Published As

Publication number Publication date
KR20200015439A (ko) 2020-02-12
IL266518A (en) 2019-07-31
WO2018089804A1 (en) 2018-05-17
CN110691612A (zh) 2020-01-14
CA3043283A1 (en) 2018-05-17
AU2017357759A1 (en) 2019-06-06
CN110691612B (zh) 2024-11-08
US20190321328A1 (en) 2019-10-24
WO2018089804A9 (en) 2018-06-21
US12377067B2 (en) 2025-08-05
EP3538154B1 (en) 2025-09-03
EP3538154A1 (en) 2019-09-18
IL323354A (en) 2025-11-01
JP2025131627A (ja) 2025-09-09
CN119367341A (zh) 2025-01-28
JP2023029865A (ja) 2023-03-07
KR20230021186A (ko) 2023-02-13
KR20240068077A (ko) 2024-05-17
AU2023263497B2 (en) 2025-09-18
JP2019533713A (ja) 2019-11-21
AU2023263497A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
MA46750A (fr) Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents
EP3226848A4 (en) METHOD FOR TREATING ALOPECIA AREATA USING GENE MODULATION APPARATUS
EP3471780A4 (en) TREATMENT OF AMD WITH AAV2 VARIANT WITH AFLIBERCEPT
MA46954A (fr) Méthodes de traitement d'états inflammatoires
EP3668500A4 (en) METHOD OF TREATMENT OF OSTEOARTHRITIS WITH TRANSDERMAL CANNABIDIOL GEL
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
EP3436052A4 (en) TREATMENT OF MUSCLE WEAKNESS WITH ALKALINE PHOSPHATASES
EP3436020A4 (en) METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
EP3340971A4 (en) METHOD FOR TREATING LENNOX-GASTAUT SYNDROME WITH FENFLURAMINE
EP3349581A4 (en) HEPATITIS B CORE PROTEIN MODULATORS
MA42450A (fr) Méthodes de traitement de la stéatose hépatique non alcoolique et/ou de la lipodystrophie
EP3426286A4 (en) PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
EP3512524A4 (en) METHOD AND COMPOSITIONS FOR TREATING VIRUS INFECTIONS
EP3302379A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PTERYGIUM
EP3423100A4 (en) COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION AND METHOD FOR THE TREATMENT THEREOF
EP3432891A4 (en) METHOD FOR THE TREATMENT AND PREVENTION OF C. DIFFICILE
EP3519058C0 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF HAIR
EP3405191A4 (en) METHOD AND COMPOSITIONS FOR TREATING HYPERHIDROSIS
EP3285776A4 (en) METHOD FOR TREATING BACTERIAL INFECTIONS
EP3426777A4 (en) COMBINATION VECTORS AND METHOD FOR THE TREATMENT OF CANCER
MA41120A (fr) Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
MA46967A (fr) Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
MA43230A (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
EP3400008A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD FOR THE TREATMENT OF HEPATITIS B
EP3368048A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSE